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Abstract
Background: Induction of apoptosis is one strategy for treatment of prostate cancer. The Shb
adapter protein has been found to regulate apoptosis in various cell types and consequently human
prostate cancer 3 (PC3) cells were transfected to obtain cells overexpressing Shb in order to
increase our understanding of the mechanisms regulating PC3 cell apoptosis.
Methods: Human prostate cancer cells (PC3) were transfected with control vector or a vector
containing the Shb cDNA. Clones overexpressing Shb were studied with respect to apoptosis
(Dapi, M30) and c-Abl activation (Western blot for pY-245-Abl). The cells were exposed to the
anti-tumor agent 2-methoxyestradiol (2-ME) and the p38 MAPK and c-Abl inhibitors SB203580 and
STI-571, respectively, after which cell death was determined. In vivo tumor growth and tumor cell
proliferation (Ki-67 staining) or apoptosis (active caspase 3 staining) were also determined in nude
mice.
Results: PC3 cells overexpressing Shb exhibited increased rates of apoptosis in the presence of
the anti-tumor agent 2-ME. The Shb cells displayed increased activity of the pro-apoptotic kinase
c-Abl. Pre-treatment with p38 MAPK (SB203580) or c-Abl (STI-571) inhibitors completely blocked
2-ME-induced apoptosis, implicating these two pathways in the response. The PC3-Shb cells
displayed reduced tumor growth in vivo, an effect occurring as a consequence of increased
apoptosis and reduced DNA synthesis.
Conclusion: It is concluded that Shb promotes 2-ME-induced PC3 cell apoptosis by increased pro-
apoptotic signaling via the c-Abl pathway and that this causes reduced tumor growth in vivo.
Background
Prostate cancer is the cause of more than 1% of all deaths
in men and its incidence is increasing by 2–3% per year
[1]. The general prognosis for diagnosed prostate cancer
remains poor and advanced prostate cancer is difficult to
treat successfully. Current therapies show many side
effects [2]. The endogenous estradiol-17β metabolite, 2-
methoxyestradiol (2-ME) exhibits many promising signs
as a candidate for future therapy of prostate cancer since
treatment with 2-ME has been found to induce apoptosis
in prostate cancer cells [3], while simultaneously exhibit-
ing low toxicity to the organism. In addition, 2-ME inhib-
its angiogenesis [4] and reduces prostate cancer growth in
vivo [3]. The growth inhibitory effects of 2-ME are associ-
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increased stability of microtubules and thereby cell cycle
arrest [4-6]. The anti-angiogenic effects exerted by 2-ME
have been linked to its inhibitory effects on hypoxia-
inducible factor-1 (HIF-1) which regulates the pro-ang-
iogenic vascular endothelial growth factor (VEGF) [7].
Interestingly, 2-ME has been reported to selectively pro-
mote cell death of human leukemia cells but not normal
lymphocytes, due to its inhibitory effects on the transcrip-
tion of the superoxide dismutase (SOD) enzymes [8].
Tumor cells are more dependent on SOD than normal
cells, as they have higher production of superoxide radi-
cals than normal cells. 2-ME is currently under phase I and
II clinical trials.
The molecular mechanisms responsible for the cytotoxic
effects of 2-ME on prostate cancer cells are only partly
known, involving activation of the p38 mitogen-activated
protein kinase (p38 MAPK) and the c-Jun N-terminal
kinase (JNK) [3,9]. These stress kinases are important
transducers of signals from the cell membrane to the
nucleus and may cause apoptosis [10]. A recent study
describes the involvement of Smad7 in the 2-ME apop-
totic pathway as well [11]. Suppression of Smad7 contents
in prostate cancer cells in vitro prevented the activation of
p38 MAPK and subsequent apoptosis [11]. The cytotoxic
response to 2-ME is thus complex and multifaceted.
Shb is an adapter protein operating downstream of certain
tyrosine kinase receptors, such as the PDGF (platelet-
derived growth factor) receptors and FGF (fibroblast
growth factor) receptor-1 [12,13]. Shb generates protein
complexes in response to activation through the assembly
of signaling components via binding of these to the differ-
ent domains of Shb [13,14]. Shb is pleiotropic and regu-
lates various responses, such as apoptosis, cell migration,
proliferation and differentiation [12]. Shb is a prototype
for a family of adapter proteins, comprising Shb and the
other members Shd, She, Shf and Shg [15,16]. All of these
share a homologous SH2 domain and four conserved
tyrosine phosphorylation sites. As of yet, the mechanisms
by which Shb regulates cell apoptosis have remained
unresolved. However, a clue as to how Shb exerts this
function may come from the observation that the Shb
homologue, Shd, binds c-Abl [16]. The non-receptor tyro-
sine kinase c-Abl is ubiquitously expressed and forms
together with the Abl-related kinase (Arg) a subfamily of
kinases that controls cell death under certain conditions
[17,18]. The activity of c-Abl is under tight control, and
binding of the c-Abl SH2 domain to its binding partners
causes a conformational change that may activate the
kinase [19]. Activation of c-Abl is associated with phos-
phorylation of regulatory tyrosine residues, such as Y245
and Y412 [20]. Several conditions of cell stress induce c-
Abl activation, and consequently cell cycle arrest and cyto-
toxic signaling eventually causing apoptosis ensues
[17,18]. We have recently described an interaction
between Shb and c-Abl that regulates apoptosis [21].
To address a potential role of Shb in PC3 cell apoptosis,
cells were transfected with Shb and clones overexpressing
Shb obtained. Rates of apoptosis and the activation of var-
ious signaling pathways were then assessed. It is con-
cluded that Shb sensitizes PC3 cells to apoptotic stimuli,
an effect that may require augmented c-Abl activation.
Methods
Cell culture and reagents
Human prostate cancer cells (PC3) were obtained from
ATCC and grown in cell culture medium RPMI 1640 sup-
plemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, penicillin (100 IU/ml), in 95% air and 5%
CO2. 2-Methoxyestradiol (2-ME), PD98059 and
LY294002 were obtained from Sigma Chemical (St. Louis,
MO, USA) and was dissolved in DMSO at a concentration
of 10 mM. In all 2-ME experiments, DMSO alone was
added to the control. SB203580 was obtained from Calbi-
ochem (La Jolla, CA, USA). STI571 (Imatinib, mesylate or
Gleevec) was obtained from Novartis and was dissolved
in H2O at a concentration of 10 mM.
Transfection of PC3 cells with Shb
One day after plating, PC3 cells were transfected with 3 µg
Shb cDNA in pcDNA1 [22] plus 0.3 µg pcDNA3 using the
Lipofectamine™ method [23] (Invitrogen, Carlsbad, CA)
in 600 µl of Opti-MEM (Gibco, Grand Island, NY) for 3
hours. Clonal selection was initiated after two days by
addition of 0.4 mg/ml G418. In parallel, cells were trans-
fected with the neomycin resistance gene only (0.3 µg
pcDNA3) for generating appropriate control cells. After
10–14 days, clones were isolated and expanded further.
Thirty six clones transfected with the Shb cDNA were ana-
lyzed for Shb expression by Western blot analysis, and five
of them were found to contain significantly elevated con-
tents of Shb.
Western blot analysis
One day after plating PC3 control or PC3-Shb cells (105
cells) in 3 cm dishes, these were treated with 10 µM of 2-
ME for different time periods (0, 30, 60, 120, 360 min),
washed with PBS and lysed directly in 150 µl of lysis
buffer (2% SDS, 0.15 M Tris-HCL pH 8,8, 10% glycerol,
5% β-mercaptoethanol, bromophenolblue and 2 mM
phenylmethylsulphonyl fluoride), boiled for 5 min and
separated on SDS-PAGE. Proteins were electrophoretically
transferred to Immobilon filters and blocked in 5%
bovine serum albumin for at least one hour, after which
the filters were incubated with antibodies against the fol-
lowing proteins: phosphorylated and total p38 (Cell Sig-
naling, Beverly, MA) and phosphorylated and total c-AblPage 2 of 9
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Santa Cruz, CA). These phosphospecific antibodies recog-
nize well-characterized activation sites of the correspond-
ing kinases. After a brief wash with TBS + 0.1% Tween 20,
membranes were probed with HRP-linked secondary anti-
bodies (1:1000) for one hour and extensively washed. Sig-
nals were detected by an enhanced chemiluminescence
(ECL) system.
Detection of apoptosis by DAPI and M30 staining
PC3 cells (control or Shb overexpressing) were treated or
not with STI-571 or with SB203580, either alone or
together with 2-ME. The SB203580 (p38 inhibitor) was
added to the media 1 h and STI-571 (c-Abl inhibitor) 9 h
before 2-ME was administered to the cells (in the presence
of the inhibitor) for 12 hours. Cells were fixed in ice-cold
methanol solution for 10 minutes prior to staining for
DAPI (4,6-diamidino-2-phenylindole dihydrochloride)
or M30. Thereafter, the slides were stained as previously
described [24]. In that study, the criteria defining apopto-
sis, ie nuclear pyknosis and fragmentation, are described.
The number of nuclei showing morphological characteris-
tics of apoptosis, were counted as positive in a Zeiss
immunofluorescence microscope at 40× magnification.
Three samples from each treatment group were evaluated.
For each sample, at least 300 nuclei were counted. In
order to validate the apoptotic effect of 2-ME using an
independent assay, cells were stained for M30. The M30-
antibody specifically recognizes caspase cleaved cytokera-
tin 18. The cells were stained for M30 according to the
protocol provided by the manufacturer, and positive cells
were counted as above.
Detection of proliferation by Ki67-staining of tumor 
sections
Tumors were fixed in 10% formaldehyde and paraffin-
embedded. Proliferating cells were detected on control or
Shb-overexpressing tumor sections after heat-induced
antigen retrieval in 0.01 M citrate buffer, pH 6.0 using the
anti-rat Ki-67 antibody (MIB-5; DakoCytomation). After
incubation with horseradish peroxidase-conjugated sec-
ondary antibody, immune complexes were visualized
with diaminobenzidine tetrahydrochloride (DAB) precip-
itates, and the sections were then mounted permanently
after nuclear counterstaining with Mayer's Hematoxylin.
Fore each tumor, more than 250 nuclei were counted for
Ki-67 positivity (dark brown nuclear stain) and the per-
centage calculated.
Detection of apoptosis by caspase 3- staining of the tumor 
sections
Apoptosis of tumor sections was determined using an
antibody against the activated form of caspase-3 (Cleaved
Caspase-3 (Asp175) Ab; Cell Signaling). The cells positive
for cleaved, active caspase-3 were visualized as above with
DAB precipitates after incubation with horseradish perox-
idase-conjugated secondary antibody. For each tumor,
more than 250 cells were counted for active caspase 3 pos-
itivity (brown cellular cytoplasm) and the percentage cal-
culated.
In vivo tumor growth
Animal experimentation had been approved by the Upp-
sala Animal Ethics Committee. Control PC3 or PC3-Shb
(clone 14) cells (4 × 106) were inoculated subcutaneously
behind the left or right forelimb on the back of nude
female mice (C57Bl6 nu/nu, Taconic, Denmark) of 8
weeks of age [25,26]. Each group of cells was inoculated
to ten mice (20 mice in total). The cells had been
trypsinized and respuspended in 0.2 ml full culture
medium prior to inoculation using a 0.6 mm needle. The
appearance of tumors was carefully monitored at the time
points indicated in the figure and tumor size was meas-
ured by a slide caliper and determined by the formula
0.44 × A × B2 where A indicates tumor base diameter one
direction and B the corresponding perpendicular value.
The tumor studies were terminated by decapitation at the
time points indicated in the figure or after 61 days when
the tumors reached a size of 1 cm3 or started to recede
(PC3-Shb tumors). The tumors were rapidly taken out
and fixed in 10% formaldehyde before histological analy-
sis.
Statistical analysis
Means ± SEM for the number of observations were deter-
mined for each experimental group. Differences were
assessed using a two-tailed Students' t-test except for
tumor growth, in which a parametric test (Mann-Whitney
U-test) was used.
Results
Effects of Shb on prostate cancer PC3 cell apoptosis
The current investigation was conducted in order to
ascribe a role of Shb in prostate cancer cell apoptosis,
since previous studies have implicated Shb in the regula-
tion of apoptosis in other cell types [12]. For this purpose,
PC3 prostate cancer cells were transfected with the Shb
cDNA and subjected to clonal selection. Figure 1A shows
Shb protein levels in one control transfected clone and
four Shb transfected clones. Two of the Shb clones (clones
number 8 and 14) exhibit elevated levels (two- to five-fold
increase) of Shb protein expression. In addition, three
additional clones (numbered 9, 12 and 18) with similarly
increased Shb protein levels as that of clone 8 were found
(results not shown).
Next, the basal growth characteristics of the Shb cells were
tested (Figure 1B). Although equal numbers of cells were
plated on day 0, the two Shb clones displayed fewer cells
on day 1 than the control clones. However, all clones,Page 3 of 9
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Shb protein expression in control and Shb-transfected PC3 cells (A)Figure 1
Shb protein expression in control and Shb-transfected PC3 cells (A). Different clones of PC3 cells transfected with Shb and 
one control-transfected clone were subjected to Western blot analysis for Shb protein as previously described [22]. Equal pro-
tein loading was assessed by ERK-protein analysis of the blot. Effect of Shb-overexpression on growth of control and Shb-over-
expressing PC3 cells during 3 days (B). On day 0, cells from the different clones were trypsinized and counted in a 
hemocytometer, after which 10000 cells were plated in each well. Cell numbers were determined by counting in a hemocy-
tometer on day one and three. 2-ME-induced apoptosis in control and Shb-overexpressing PC3 cells (C). Percentages of cells 
undergoing apoptosis as based upon DAPI nuclear staining and M30 staining were determined in three control clones and five 
clones overexpressing Shb after treatment (or not) with 10 µM 2-ME for 12 h. The experiments were carried out in duplicates 
in 3 separate experiments performed on different occasions, in which 200–600 cells from each treatment condition were 
counted at 40× magnification in a Zeiss immunofluorescence microscope. The mean values ± SEM are presented.
BMC Cancer 2007, 7:161 http://www.biomedcentral.com/1471-2407/7/161both control and Shb-overexpressing, showed a similar
increase in their cell numbers between day one and three.
Thus, Shb overexpression does not affect the ability of
PC3 cells to proliferate, although it causes these cells to
become sensitized to trypsinization.
2-ME is a drug that presently is under evaluation for clin-
ical treatment of prostate cancer due to its ability to cause
prostate cancer cell apoptosis [9]. It was thus of interest to
study PC3 cell apoptosis upon 2-ME treatment in the Shb-
overexpressing cells (Figure 1C). Two separate assays were
used for the determination of apoptosis: nuclear conden-
sation and pyknosis determined by DAPI staining, and
M30 staining for cytokeratin 18 cleavage [24,27]. Both
assays detect apoptosis among adherent cells at the time
of assay. All clones (both control and Shb-overexpressing)
responded to 2-ME with increased rates of apoptosis. In
addition, Shb-overexpression caused increased rates of
apoptosis in the presence of 2-ME as compared with the
three control clones. Also, it appeared as if Shb-overex-
pression increased apoptosis in the absence of 2-ME,
although the percentage cells undergoing apoptosis was
in most experiments less than 5%.
Shb-overexpression increases c-Abl activity
The effects of Shb on signaling pathways were investigated
to find an explanation for the altered rates of apoptosis in
PC3-Shb cells. The c-Abl tyrosine kinase is responsible for
various apoptotic responses [17,18]. A Shb homologue,
Shd [16], was found to interact with c-Abl, and we have
recently reported an interaction between Shb and c-Abl
that is of importance for regulation of apoptosis [21], rais-
ing the possibility that this kinase is involved in the Shb-
effect. Figure 2 shows increased c-Abl activation/phospho-
rylation in the Shb PC3 cells without 2-ME addition. In
addition, these cells responded with an additional
increase of c-Abl activation in response to incubation for
two hours in the presence of 2-ME that was statistically
significant. Thus, the augmented apoptotic response to
Shb-overexpression could involve c-Abl activation.
Effects of p38 inhibition and c-Abl inhibition on Shb-
dependent apoptosis
To assess the contribution of c-Abl activation in Shb-
dependent apoptosis in response to 2-ME, control and
Shb-overexpressing PC3 cells were pre-treated with the c-
Abl inhibitor STI-571 (Gleevec) prior to 2-ME exposure
(Figure 3). 2-ME-induced apoptosis was completely sup-
pressed in both the control and Shb cells. Previously, acti-
vation of the p38 MAPK has been also implicated in 2-
ME-induced PC3 cell apoptosis [11]. We assessed p38
MAPK activation by Western blot analysis employing an
antibody that recognizes activated p38. The results
revealed that 2-ME caused p38 activation in both the con-
trol and PC3-Shb cells in a manner that was indistinguish-
able between these groups of cells with respect to the
kinetics and magnitude of p38 stimulation (results not
shown), suggesting that the effect of Shb does not involve
p38 MAPK. The involvement of p38 MAPK was further
examined by pre-treatment of cells with the p38 inhibitor
SB203580 and studying 2-ME induced apoptosis. Again,
the 2-ME response was completely suppressed in the con-
trol and Shb cells. The data suggest activation of both the
p38 and c-Abl pathways as necessary for 2-ME-induced
PC3 cell apoptosis.
In vivo tumor growth
Nude mice were injected with PC3-control or PC3-Shb
cells after which tumor growth was monitored [25,26].
The tumor take rate of the control cells was 6 out of 10.
For the Shb cells, the tumor take rate was 3 out of 10. The
Shb-overexpression affects the phosphorylation of c-Abl in PC3 cellsFigur  2
Shb-overexpression affects the phosphorylation of c-Abl in 
PC3 cells. Control and Shb-overexpressing PC3 cells (clone 
14) were plated at equal numbers and 36 hours later treated 
with 10 µM of 2-ME for indicated time periods, after which 
all cells were lysed in SDS-sample buffer. A: Western blot 
analysis. The blot was probed for pY245-c-Abl and total c-
Abl. The blot was also probed for beta-actin and total ERK to 
assess loading. B: pY-c-Abl over total c-Abl was determined 
by densitometry and given in arbitrary units. Means ± SEM 
for 4–6 separate experiments utilizing two control and five 
Shb-overexpressing clones are shown. * indicates p < 0.05 
when compared with the PC3-Shb zero time point using a 
Students' t-test.Page 5 of 9
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Although the Shb tumors became visually detectable at a
similar time point, their subsequent growth was much
slower (Figure 4). All three of the PC3-Shb tumors
regressed when they reached a size of 14, 50 and 170
mm3, respectively. These animals were sacrificed before
complete disappearance of the tumors (arrow indicates
sacrifice of the mouse carrying the first tumor that
regressed, the others were sacrificed after 61 days when
their regression was severe but not complete). The control
tumors were retrieved either when they reached a volume
of 1 cm3 as indicated by the arrows or at the end of the
experiment. Tumor morphology, tumor cell proliferation
assessed by Ki67-staining and tumor cell apoptosis visual-
ized by staining for active caspase-3 was then determined
on histological sections (Figure 4). No obvious differences
in tumor histological morphology were noted between
the control or Shb tumors. However, when examining
rates of tumor cell apoptosis after the significant reduction
in the Shb tumor sizes, the Shb tumors were found to dis-
play elevated rates of apoptosis (Figure 4). Furthermore,
their rates of DNA synthesis were reduced. The data sug-
gest that Shb-overexpression reduces PC3 cell in vivo
tumor growth as a consequence of a combined effect on
apoptosis and DNA synthesis.
Discussion
As previously reported in fibroblasts [22], pancreatic islet
beta-cells [28] and endothelial cells [29,30], overexpres-
sion of the SH2 domain adapter protein Shb in human
prostate cancer cells (PC3) also causes increased apoptosis
under certain conditions. Particularly the increased apop-
totic response to 2-ME is of interest since 2-ME is currently
under consideration in clinical trials as a therapy for pros-
tate cancer. Elucidation of the mechanisms of the Shb
effect in this context may provide additional insight into
the action of 2-ME that could eventually bear fruit in the
form of novel clinical applications.
Previous work has implicated activation of p38 MAPK and
increased Smad7 as signaling events responsible for the
action of 2-ME [11,31]. Although p38 activation was
noted in response to 2-ME in the Shb cells, this effect was
not accentuated, suggesting that Shb uses another path-
way to promote 2-ME-induced apoptosis. The Smad7 con-
tent and GSK-3β kinase activity were not affected by Shb
overexpression (results not shown), arguing against an
involvement of these pathways in the Shb effect.
Shb activates the pro-apoptotic kinase c-Abl. We have
recently observed interactions between Shb and c-Abl that
have a bearing on the regulation of apoptosis [21], and
our present observations are in line with this. Numerous
apoptotic pathways have been reported to be activated by
c-Abl, for example p73 [32], p38 MAPK [33], JNK (c-Jun
N-terminal kinase) [33], as well as inactivation of NF-κB
[34]. In this study, we have not explored the p73 and NF-
κB pathways, but we could not detect activation of JNK in
the control or Shb cells (results not shown) and p38
MAPK was activated to a similar extent in the control and
Shb cells (results not shown), leaving the downstream sig-
naling pathways of c-Abl presently operating unknown.
To verify the participation of the c-Abl pathway as respon-
sible for Shb-dependent 2-ME-induced death, cells were
treated with the c-Abl inhibitor STI-571 (Gleevec). This
completely blocked 2-ME-induced death. STI-571 is not
entirely specific for c-Abl, and may inhibit the PDGF
receptors as well [35]. However, the presently described
effect of STI-571 is not likely to involve the PDGF recep-
tors, since PDGF reduces Shb-dependent cell death [22].
In vivo trials employing STI-571 as treatment of prostate
cancer via PDGF receptor inhibition have been initiated
[36]. However, anti-apoptotic effects of STI-571 via c-Abl
inhibition could be a complicating factor confounding
the interpretation of such in vivo studies.
The overexpression of Shb also causes reduced in vivo
tumor growth of PC3 cells. This effect occurs in the
absence of 2-ME treatment and is pronounced. In addi-
tion, it occurs as a consequence of a combined effect on
2-ME-induced apoptosis in control and Shb-overexpressing (clone 14) PC3 cellsFigure 3
2-ME-induced apoptosis in control and Shb-overexpressing 
(clone 14) PC3 cells. Cells were treated or not with 10 µM 
of 2-ME in the absence or presence of a p38 (SB203580) or 
c-Abl (STI-571) inhibitor. The inhibitor was added to the 
media 1–9 h before initiation of 2-ME treatment. Cells were 
treated for 12 h, before fixation and staining with DAPI and 
M30 for assessing apoptosis. The experiments were carried 
out in duplicates in 3 separate experiments, where 200–600 
cells from each treatment condition was counted at 40 × 
magnification in a Zeiss immuno-fluorescence microscope. 
Means ± SEM are shown.Page 6 of 9
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perturbation that Shb causes in intracellular signaling, ie
activated pro-apoptotic signaling via c-Abl, will create an
intracellular milieu unsupportive of tumor growth in
vivo. However, the data do not exclude alternative possi-
bilities, for example that the effects are secondary to other
processes, such as reduced angiogenesis, despite the fact
that we could not detect any major differences in vascular-
ization between the control or Shb tumors.
The data suggest that both the c-Abl and p38 MAPK path-
ways are required for 2-ME-induced PC3 cell death, since
addition of these inhibitors completely blocked the 2-ME
effect. Understanding the presently described Shb-
dependent augmentation of pro-apoptotic signaling via c-
Abl could provide additional measures for improving
prostate cancer therapy in vivo.
Conclusion
Overexpression of the Shb adapter protein causes
increased apoptosis of human prostate cancer PC3 cells in
response to the anti-tumor agent 2-ME. This is likely to
result from increased c-Abl activity. As a consequence of
Shb overexpression, there is reduced tumor growth in
vivo. Promoting Shb signaling may generate means to
improve prostate cancer treatment.
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In vivo tumor growth of control or Shb-overexpressing PC3cellsFigure 4
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mice. Tumor growth was carefully monitored. The tumor take rate was 6/10 for the control PC3 cells and 3/10 for the Shb-
overexpressing PC3 cells (clone 14). All PC3-Shb tumors regressed when they reached a size of 14, 50 and 170 mm3, respec-
tively. Means tumor volume ± SEM are given. Arrows indicate sacrifice of mice due to the tumor size approaching 1 ml in the 
controls or in the Shb case tumor regression. * indicates p < 0.05 when tested against control using a Mann-Whitney U-test. B. 
PC3 control or PC3-Shb tumor cell morphology after staining for Hematoxylin-Eosin (HE), active caspase 3 or Ki-67. A nega-
tive control for active caspase 3 staining is also shown. Arrows indicate cells positive for caspase 3. Original magnification was 
100× for HE and 400× for Ki-67 and caspase 3. Horizontal bars in subpanels indicate 50 µm. C. PC3 control or PC3-Shb tumor 
cell apoptosis or proliferation after staining for active caspase-3 or Ki-67. Percentage cells positive for active caspase-3 are 
given. Means ± SEM for 6 or 3 observations, respectively. * indicates p < 0.05 with a Student's t-test. Tumor cell DNA synthe-
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